Explore

Trendline Trendline
Cytospire Secures $83 Million for Innovative T-Cell Engager Platform Targeting Cancer

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform Targeting Cancer

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform Targeting Cancer
Trendline Trendline
Cytokinetics to Release Phase 3 Trial Results for Aficamten in Heart Disease Treatment

Cytokinetics to Release Phase 3 Trial Results for Aficamten in Heart Disease Treatment

Cytokinetics to Release Phase 3 Trial Results for Aficamten in Heart Disease Treatment
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions
Trendline Trendline
Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals
Trendline Trendline
ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients

ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients

ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients
Trendline Trendline
Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks

Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks

Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks
Trendline Trendline
Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease
Trendline Trendline
Allarity Therapeutics Advances Stenoparib with Phase 3 Manufacturing Campaign for Cancer Treatment

Allarity Therapeutics Advances Stenoparib with Phase 3 Manufacturing Campaign for Cancer Treatment

Allarity Therapeutics Advances Stenoparib with Phase 3 Manufacturing Campaign for Cancer Treatment
Trendline Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables
Trendline Trendline
Ascletis to Present Obesity Treatment Data at European Congress

Ascletis to Present Obesity Treatment Data at European Congress

Ascletis to Present Obesity Treatment Data at European Congress
Trendline Trendline
FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data